Logo image of JAZZ

JAZZ PHARMACEUTICALS PLC (JAZZ) Stock Overview

NASDAQ:JAZZ - IE00B4Q5ZN47 - Common Stock

128.02 USD
-3.7 (-2.81%)
Last: 9/4/2025, 8:15:32 PM
127.72 USD
-0.3 (-0.23%)
After Hours: 9/4/2025, 8:15:32 PM

JAZZ Key Statistics, Chart & Performance

Key Statistics
52 Week High148.06
52 Week Low95.49
Market Cap7.77B
Shares60.66M
Float58.76M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)6.64
PE19.28
Fwd PE5.82
Earnings (Next)11-04 2025-11-04/amc
IPO01-18 2012-01-18
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals


JAZZ short term performance overview.The bars show the price performance of JAZZ in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 5 -5 10 15 20

JAZZ long term performance overview.The bars show the price performance of JAZZ in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 5 10 15

The current stock price of JAZZ is 128.02 USD. In the past month the price increased by 20.85%. In the past year, price increased by 19.49%.

JAZZ PHARMACEUTICALS PLC / JAZZ Daily stock chart

JAZZ Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 46 703.13B
JNJ JOHNSON & JOHNSON 17.88 430.51B
AZN ASTRAZENECA PLC-SPONS ADR 18.42 253.56B
NVO NOVO-NORDISK A/S-SPONS ADR 14.39 249.45B
NVS NOVARTIS AG-SPONSORED ADR 14.51 248.60B
MRK MERCK & CO. INC. 10.92 209.94B
PFE PFIZER INC 7.24 139.52B
SNY SANOFI-ADR 10.26 110.56B
BMY BRISTOL-MYERS SQUIBB CO 6.94 95.03B
GSK GSK PLC-SPON ADR 8.78 79.80B
ZTS ZOETIS INC 24.63 67.90B
TAK TAKEDA PHARMACEUTIC-SP ADR 52.72 48.29B

About JAZZ

Company Profile

JAZZ logo image Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. The company is headquartered in Dublin, Dublin and currently employs 2,800 full-time employees. The company went IPO on 2012-01-18. The company is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. The company has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.

Company Info

JAZZ PHARMACEUTICALS PLC

Fifth Floor, Waterloo Exchange, Waterloo Road, Dublin 4

DUBLIN DUBLIN D04 IE

CEO: Bruce C. Cozadd

Employees: 2800

JAZZ Company Website

JAZZ Investor Relations

Phone: 35316347800

JAZZ PHARMACEUTICALS PLC / JAZZ FAQ

What is the stock price of JAZZ PHARMACEUTICALS PLC today?

The current stock price of JAZZ is 128.02 USD. The price decreased by -2.81% in the last trading session.


What is the ticker symbol for JAZZ PHARMACEUTICALS PLC stock?

The exchange symbol of JAZZ PHARMACEUTICALS PLC is JAZZ and it is listed on the Nasdaq exchange.


On which exchange is JAZZ stock listed?

JAZZ stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for JAZZ PHARMACEUTICALS PLC stock?

25 analysts have analysed JAZZ and the average price target is 187.39 USD. This implies a price increase of 46.38% is expected in the next year compared to the current price of 128.02. Check the JAZZ PHARMACEUTICALS PLC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is JAZZ PHARMACEUTICALS PLC worth?

JAZZ PHARMACEUTICALS PLC (JAZZ) has a market capitalization of 7.77B USD. This makes JAZZ a Mid Cap stock.


How many employees does JAZZ PHARMACEUTICALS PLC have?

JAZZ PHARMACEUTICALS PLC (JAZZ) currently has 2800 employees.


What are the support and resistance levels for JAZZ PHARMACEUTICALS PLC (JAZZ) stock?

JAZZ PHARMACEUTICALS PLC (JAZZ) has a support level at 120.8. Check the full technical report for a detailed analysis of JAZZ support and resistance levels.


Is JAZZ PHARMACEUTICALS PLC (JAZZ) expected to grow?

The Revenue of JAZZ PHARMACEUTICALS PLC (JAZZ) is expected to grow by 4.27% in the next year. Check the estimates tab for more information on the JAZZ EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy JAZZ PHARMACEUTICALS PLC (JAZZ) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does JAZZ PHARMACEUTICALS PLC (JAZZ) stock pay dividends?

JAZZ does not pay a dividend.


When does JAZZ PHARMACEUTICALS PLC (JAZZ) report earnings?

JAZZ PHARMACEUTICALS PLC (JAZZ) will report earnings on 2025-11-04, after the market close.


What is the Price/Earnings (PE) ratio of JAZZ PHARMACEUTICALS PLC (JAZZ)?

The PE ratio for JAZZ PHARMACEUTICALS PLC (JAZZ) is 19.28. This is based on the reported non-GAAP earnings per share of 6.64 and the current share price of 128.02 USD. Check the full fundamental report for a full analysis of the valuation metrics for JAZZ.


What is the Short Interest ratio of JAZZ PHARMACEUTICALS PLC (JAZZ) stock?

The outstanding short interest for JAZZ PHARMACEUTICALS PLC (JAZZ) is 9.57% of its float. Check the ownership tab for more information on the JAZZ short interest.


JAZZ Technical Analysis

ChartMill assigns a technical rating of 9 / 10 to JAZZ. When comparing the yearly performance of all stocks, JAZZ is one of the better performing stocks in the market, outperforming 75.87% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

JAZZ Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to JAZZ. There are concerns on the financial health of JAZZ while its profitability can be described as average.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

JAZZ Financial Highlights

Over the last trailing twelve months JAZZ reported a non-GAAP Earnings per Share(EPS) of 6.64. The EPS decreased by -62.78% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -3.7%
ROE -10.92%
Debt/Equity 1.17
Chartmill High Growth Momentum
EPS Q2Q%-255.66%
Sales Q2Q%2.14%
EPS 1Y (TTM)-62.78%
Revenue 1Y (TTM)4.52%

JAZZ Forecast & Estimates

25 analysts have analysed JAZZ and the average price target is 187.39 USD. This implies a price increase of 46.38% is expected in the next year compared to the current price of 128.02.

For the next year, analysts expect an EPS growth of -74.75% and a revenue growth 4.27% for JAZZ


Analysts
Analysts84.8
Price Target187.39 (46.38%)
EPS Next Y-74.75%
Revenue Next Year4.27%

JAZZ Ownership

Ownership
Inst Owners102.03%
Ins Owners2.44%
Short Float %9.57%
Short Ratio7.49